Liquidia Corp shares are trading higher after the U.S. Supreme Court declined to review rulings and announced that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics.
Portfolio Pulse from Benzinga Newsdesk
Liquidia Corp shares rose after the U.S. Supreme Court declined to review rulings, confirming that Liquidia does not infringe on United Therapeutics' patents.
October 07, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Liquidia Corp's stock price increased following the U.S. Supreme Court's decision not to review rulings, which confirmed that Liquidia does not infringe on United Therapeutics' patents.
The Supreme Court's decision removes a significant legal overhang for Liquidia, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100